Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Spoorendonk, J. A.
97  Ergebnisse:
Personensuche X
?
1

Clinical implications and cost-effectiveness analysis of ri..:

Spoorendonk, J. A. ; Briere, J.-B. ; Bowrin, K....
Journal of Medical Economics.  24 (2021)  1 - p. 1231-1239 , 2021
Link: https://doi.org/10.1080/..
 
?
2

PCN21 Efficacy and Safety in Previously Untreated, Advanced..:

Kraan, C.W. ; Nientker, L. ; May, J....
Value in Health.  23 (2020)  - p. S424 , 2020
Link: https://doi.org/10.1016/..
 
?
3

PCN42 Real-World Effectiveness in Previously Untreated, Adv..:

Trip, A.M. ; May, J. ; Malcolm, B....
Value in Health.  23 (2020)  - p. S428 , 2020
Link: https://doi.org/10.1016/..
 
?
4

PCN183 Global Incidence, Prevalence, and Survival in Relaps..:

Spoorendonk, J. ; Feng, C. ; Shah, D...
Value in Health.  23 (2020)  - p. S455 , 2020
Link: https://doi.org/10.1016/..
 
?
5

Relationship Between Patient Characteristics and Outcomes I..:

Gonzalez-McQuire, S ; Hensen, M ; Spoorendonk, J.
Value in Health.  18 (2015)  7 - p. A662 , 2015
Link: https://doi.org/10.1016/..
 
?
6

Factors Influencing Dutch Drug Reimbursement Recommendation..:

Alleman, C.J.M. ; Spoorendonk, J.A. ; Charokopou, M...
Value in Health.  17 (2014)  7 - p. A441 , 2014
Link: https://doi.org/10.1016/..
 
?
7

A Comparison of Factors Influencing Reimbursement and Cover..:

Charokopou, M. ; Alleman, C.J.M. ; Verleger, K....
Value in Health.  17 (2014)  7 - p. A430 , 2014
Link: https://doi.org/10.1016/..
 
?
8

A cost-consequence model of using the 21-gene assay to iden..:

Simons, Martijn J. H. G. ; Machielsen, Peter M. ; Spoorendonk, Jelle A....
Journal of Medical Economics.  27 (2024)  1 - p. 445-454 , 2024
Link: https://doi.org/10.1080/..
 
?
9

The feasibility of a 12-week progressive strength training ..:

Kierkegaard-Brøchner, S. ; Kemp, J. ; Lund, B....
Journal of Science and Medicine in Sport.  26 (2023)  - p. S123-S124 , 2023
Link: https://doi.org/10.1016/..
 
?
10

POSB276 Network Meta-Analyses of Nivolumab Plus Fluoropyrim..:

Grevinga, M ; Bouwmeester, W ; Spoorendonk, JA...
Value in Health.  25 (2022)  1 - p. S180-S181 , 2022
Link: https://doi.org/10.1016/..
 
?
11

POSC64 Healthcare Costs and Resource Utilization in 1L Main..:

Heldt, D ; Snedecor, SJ ; Kalilani, L...
Value in Health.  25 (2022)  1 - p. S98-S99 , 2022
Link: https://doi.org/10.1016/..
 
?
12

CO49 Clinical Efficacy and Safety of Therapeutic Interventi..:

Jain, P ; Badgujar, L ; Spoorendonk, JA.
Value in Health.  25 (2022)  7 - p. S312-S313 , 2022
Link: https://doi.org/10.1016/..
 
?
13

POSB97 Cost-Consequence Model of Using Gene Expression Test..:

de Jongh, FE ; Efe, R ; Herrmann, K..
Value in Health.  25 (2022)  1 - p. S79-S80 , 2022
Link: https://doi.org/10.1016/..
 
?
14

MSR126 Economic and Humanistic Burden in Patients With Obst..:

Spoorendonk, JA ; Şahbaz Gülser, S ; Arca`, E...
Value in Health.  25 (2022)  12 - p. S374 , 2022
Link: https://doi.org/10.1016/..
 
?
15

Cost and Clinical Benefits Associated with Oncotype DX® Tes..:

de Jongh, Felix E. ; Efe, Reva ; Herrmann, Kirsten H...
International Journal of Breast Cancer.  2022 (2022)  - p. 1-12 , 2022
Link: https://doi.org/10.1155/..
 
1-15